Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study.

MLA

Jose, Sandra, et al. “Repurposing FDA-Approved Drugs as FXR Agonists: A Structure Based in Silico Pharmacological Study.” Bioscience Reports, vol. 43, no. 3, Mar. 2023. EBSCOhost, https://doi.org/10.1042/BSR20212791.

APA

Jose, S., Devi, S. S., Sajeev, A., Girisa, S., Alqahtani, M. S., Abbas, M., Alshammari, A., Sethi, G., & Kunnumakkara, A. B. (2023). Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study. Bioscience Reports, 43(3). https://doi.org/10.1042/BSR20212791

Chicago

Jose, Sandra, Sreevidya S Devi, Anjana Sajeev, Sosmitha Girisa, Mohammed S Alqahtani, Mohamed Abbas, Abdulrahman Alshammari, Gautam Sethi, and Ajaikumar B Kunnumakkara. 2023. “Repurposing FDA-Approved Drugs as FXR Agonists: A Structure Based in Silico Pharmacological Study.” Bioscience Reports 43 (3). doi:10.1042/BSR20212791.